Traders should monitor the upcoming shareholder vote on the Unleash Issuance Proposal, as approval is required for the conversion of the Series C Preferred Stock into common stock. The transaction expands TransCode's pipeline into oncolytic immunotherapy but introduces meaningful dilution. The market may react to the balance between pipeline enhancement and equity dilution, particularly given the company's small $9M market cap.
Price Chart
Executive Summary
TransCode Therapeutics filed a proxy statement (DEFA14A) related to a shareholder vote on the issuance of Series C Non-Voting Convertible Preferred Stock to Unleash Immuno Oncolytics as consideration for an exclusive license to develop oncolytic immunotherapy candidates. The transaction, structured as an all-stock deal, gives Unleash 1,136,364 shares of Series C Preferred Stock, convertible into common stock upon shareholder approval, representing 6.8% of the company on a fully diluted basis. The filing initiates the process for stockholder approval required under Nasdaq rules.
Key Facts
- TransCode issued 1,136,364 shares of Series C Non-Voting Convertible Preferred Stock to Unleash as payment for an exclusive, worldwide license to develop three preclinical oncolytic virus candidates (UIO-524, UIO-525, UIO-526).
- The Series C Preferred Stock is convertible into common stock on a 1:1 basis, but only after shareholder approval of the conversion, required under Nasdaq Listing Rule 5635.
- The shares issued to Unleash represent 6.8% of TransCode's common stock on a fully diluted basis assuming conversion of all preferred stock.
- An additional 77,841 shares of Series C Preferred Stock were issued to Tungsten Advisors as compensation for advisory services.
- The lead asset, UIO-524, targets muscle-invasive bladder cancer (MIBC) and is positioned as a next-generation therapy building on CG Oncology's CG0070.
- The company will file a proxy statement to solicit shareholder approval for the Unleash Issuance Proposal.
Financial Impact
The issuance of 1,136,364 shares of Series C Preferred Stock to Unleash, convertible into common stock, represents a 6.8% dilution on a fully diluted basis. The transaction has no immediate cash impact but increases future share count upon conversion.
Risk Factors
- Shareholder approval for the conversion is not guaranteed, which could create uncertainty and delay the full integration of the licensed assets.
- The 6.8% dilution on a fully diluted basis may be viewed negatively by existing shareholders, especially in a low-float, micro-cap stock.
- The licensed candidates (UIO-524, UIO-525, UIO-526) are preclinical, representing high-risk, long-term value with no near-term revenue potential.
- TransCode's ability to fund further development of both its existing TTX-MC138 program and the new oncolytic candidates remains a concern given its small market cap and typical cash burn of clinical-stage biotechs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-022837 |
| Document: tm267831d1_8k.htm | 0001104659-26-022837 |
| Document: tm267831d1_ex99-1.htm | 0001104659-26-022837 |
| Document: 0001104659-26-022837-index-headers.html | 0001104659-26-022837 |
| Document: 0001104659-26-022837-index.html | 0001104659-26-022837 |
| Document: 0001104659-26-022837.txt | 0001104659-26-022837 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.72 (+0.29%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.72 (−3.11%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.72 (−3.94%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.72 (−80.08%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.72 (−63.51%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.72 (−65.97%) |
May 26, 2026 22w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.72 (+68.18%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.72 (+78.10%) |
Apr 7, 2026 29w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.72 (+80.29%) |
Mar 3, 2026 33w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.72 (−82.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers